AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2011
Apr 13, 2011
33422_dirs_2011-04-13_3a8a875a-50f4-4445-a830-5c92b773a838.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 5 — Annual Statement of Changes in Beneficial Ownership
Issuer: PRO PHARMACEUTICALS INC (PRWP)
CIK: 0001133416
Period of Report: 2010-12-31
Reporting Person: CZIRR JAMES C (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2010-03-31 | Common Stock | J | 301952 | $0.44 | Acquired | 982783 | Indirect |
| 2010-06-30 | Common Stock | J | 358015 | $0.71 | Acquired | 1340798 | Indirect |
| 2010-09-30 | Common Stock | J | 380475 | $0.79 | Acquired | 1721273 | Indirect |
| 2010-12-31 | Common Stock | J | 380475 | $0.9 | Acquired | 2101748 | Indirect |
| 2010-09-30 | Common Stock | A | 6000 | $0.79 | Acquired | 167700 | Indirect |
Footnotes
F1: Received as a dividend on Class B Convertible Preferred Stock.
F2: Reporting Person received additional shares of Issuer's common stock as dividends in the amount of 6,000 shares. Such shares are held in by a revocable trust in which Reporting Person is the sole trustee and sole beneficiary. The number of shares issuable in payment of dividends is based upon the market price of the common stock, subject to a minimum price of $1.00 per share. The price reported is the closing price of the common stock on the date the shares were issued.